Richter, Juli M.; Schanbacher, Brandon L.; Huang, Hong; Xue, Jianjing; Bauer, John A.; Giannone, Peter J.
The mucosal lining of the gastrointestinal tract is composed of a rapidly proliferating and continually renewing sheet of epithelial cells that, when damaged in the course of daily events of digestion and motility, rapidly reseal to prevent penetration and absorption of toxic and immunogenic factors (1,2). These toxic and immunogenic factors, if absorbed, may lead to a generalized systemic inflammatory and uncontrolled immune response, as occurs in necrotizing enterocolitis (NEC) (1,2). NEC is a disease of mainly premature infants and is characterized by abnormal bacterial colonization, altered barrier function, exaggerated inflammatory response, and impaired intestinal epithelial wound healing (3–6). Intestinal mucosal surface repair occurs in several steps, the first of which involves adjacent epithelial cells migrating into the wound. This is a process known as epithelial restitution, which begins almost immediately following injury and does not require cell proliferation (1,2).
Multiple factors have been shown to alter intestinal epithelial cell migration, including lipopolysaccharide (LPS). LPS, or bacterial endotoxin, is the main component of the Gram-negative bacterial cell wall and is a potent activator of the immune system. Studies have shown that human infants with NEC have an increased amount of pathogenic Gram-negative bacteria and corresponding endotoxin in their stool (3,7), and that in animal models experimental NEC is increased with exposure to LPS or live bacteria (8). Others have demonstrated that LPS impairs intestinal epithelial restitution in vitro and in vivo (6,9).
LPS-binding protein (LBP) is an acute-phase protein synthesized in the liver and other organs and serves as a key modulator of cellular and systemic responses to LPS (10). LBP binds to the lipid A moiety of LPS and transfers LPS to membrane-bound CD14 (mCD14), which is one part of the LPS receptor (11,12). LBP is present in the serum of healthy humans at concentrations of 5 to 15 μg/mL but increases to ≥50 μg/mL during the acute-phase response (13). Recent studies have shown a duality in the effect of LBP binding to LPS; at lower basal concentrations, LBP enhances cell responses to LPS by accelerating the binding of LPS to mCD14, thus facilitating receptor agonism and ensuing host defense responses (14). In contrast, at high LBP concentrations (as in settings of an acute-phase response), LPS cellular activation can be inhibited (15).
The intestinal lumen contains high amounts of endotoxin, and the intestinal mucosa forms the interface between this potentially harmful material and the interior of the host (16). There is evidence for the synthesis of LBP in the intestinal mucosa (17), suggesting that its presence regulates or contributes to the intestinal response to LPS. Given these previous reports, we sought to determine whether recombinant LBP could serve as a potential approach to blunt enterocyte response to LPS, and thus may have value as a strategy for NEC treatment. Here we tested the hypothesis that exogenously administered LBP attenuates the effects of LPS and improves intestinal epithelial cell wound healing in vitro. We also tested the hypothesis that orally administered LBP decreases the incidence and severity of intestinal injury in a newborn rat model of NEC.
Neonatal rat enterocytes (intestinal epithelial cells [IEC-6] cells, passage <25) were obtained from ATTC (Manassas, VA) and maintained in Dulbecco modified Eagle's medium (Mediatech, Manassas, VA) containing 10% fetal bovine serum (Hyclone Laboratories Inc, South Logan, UT), 2 mmol/L L-glutamine (Mediatech), penicillin and streptomycin (Mediatech), and insulin (10 μg/mL; Gibco, Carlsbad, CA). Purified LPS from Escherichia coli 0111:B4 was obtained from Sigma (St Louis, MO). Recombinant human LBP (25 μg) was purchased from R&D Systems (Minneapolis, MN). Bromodeoxyuridine (BrdU) for the assessment of epithelial cell proliferation was obtained from Aldrich (St Louis, MO).
Pregnant Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) were obtained at gestation E16 and were allowed access to standard chow and water ad libitum until delivery of the pups via cesarean section at E21 (term). All of the animal studies were approved by The Research Institute at Nationwide Children's Hospital's institutional animal care and use committee.
Wounding assays were performed as follows: briefly, enterocytes were seeded (400,000 cells per milliliter) in poly-L-lysine–coated 8-chamber slides (Labtek II; Nunc, Rochester, NY) and grown to confluence. After the cells achieved confluence, a wound was created using a modified cell scraper attached to a microscope. The microscope stage controls allow the creation of a straight, consistent wound (width ≈ 500 μm). After wounding, media was replaced with serum-free media with or without LPS (50–100 μg/mL) in the presence or absence of LBP (0.1–50 μg/mL). LPS was mixed with LBP for 1 hour before treatment of the wounded cells. Digital images of wounds were captured using a 4× objective on an inverted microscope (Olympus, Melville, NY) with an attached digital camera (Qimaging, Surrey, Canada) at 0, 8, and 24 hours after wounding. Image analysis was performed using Image Pro Plus software (Media Cybernetics, Silver Spring, MD) and a custom-written macro. Migration was assessed by measuring the amount of area that is occupied by cells in the wound area compared with the 0-hour wound. Results are expressed as the microns of wound closure as compared with the 0-hour wound area. Experiments were performed in quadruplicate, and 3 images from each well were used to quantitate the effects of LPS and LBP on migration.
Toll-like Receptor 4 mRNA by Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) Analysis
Cells treated with LPS in the presence or absence of LBP were harvested, and total RNA was extracted with guanidine using a previously published protocol (Current Protocols in Molecular Biology).
Isolation of RNA
Enterocyte cells were lysed with 4 mol/L guanidine thiocyanate, mixed sequentially with 2 mol/L sodium acetate, pH 4, extracted with phenol, phenol/chloroform/isoamyl alcohol, and then precipitated with isopropanol. The RNA pellet was washed with 75% ethanol and then dissolved in diethylpyrocarbonate water. RNA quality was assessed examining 28s and 18s bands after agarose/formaldehyde gel electrophoresis.
RNA was reverse transcripted by MuLV Reverse Transcriptase (Applied Biosystems, Foster City, CA) with Oligo dT primer. Real-time RT-PCRs were performed on an iCycler (Bio-Rad Laboratories, Hercules, CA.) with 1-step PCR SYBR Green, 3-minute 95°C denaturation step, 40-cycle thermal cycling program composed of a 30-second denaturation step at 95°C, 10-second annealing step at 60°C, and 30-second extension step at 72°C. Real-time RT-PCR results were normalized to the ribosomal protein L30 (RPL30) housekeeping gene. Primer sequence: TLR4 sense, 5′-GGA TTT ATC CAG GTG TGA AA-3′, TLR4 antisense, 5′-TTT GTC TCC ACA GCC ACC A-3′. Products are 160 bp.
Determination of Cell Proliferation
Enterocytes were seeded in 8-chamber slides, grown to confluence in Dulbecco modified Eagle's medium with 10% fetal bovine serum and wounded as described in the wounding assays section. Media was replaced with serum-free media with or without LPS. After 8 hours of incubation at 37°C, BrdU (10 μmol/L) was added and incubated for 30 minutes. Following BrdU incubation, cells were fixed in ice-cold methanol and stained using an anti-BrdU primary antibody (Millipore, Billerica, MA), according to the manufacturer's instructions, and Alexafluor 488 goat anti-mouse secondary antibody (Molecular Probes, Eugene, OR). Cells were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (Pierce, Rockford, IL). Images were taken of each wound using DAPI and fluorescein isothiocyanate filters.
Newborn Rodent Model of NEC
Following delivery by cesarean section, rat pups were placed on the rat NEC model protocol. Each pup was given enteral LPS (1 mg/kg E coli LPS) via gavage once per day and enteral orogastric artificial feedings 6 times per day. The feedings consisted of 15 g of Similac 60/40 powder (Ross Pediatrics, Columbus, OH) added to 75-mL Esbilac Liquid Milk Replacer (Pet-Ag, New Hampshire, IL), to provide 200 kcal · kg−1 · day−1. Starting within 2 to 3 hours of delivery, pups were exposed to hypoxia (100% nitrogen) for 2 minutes followed immediately by exposure to hypothermia (10 minutes at 4°C) twice per day. Pups were also treated daily with either LBP via gavage (10 μg/mL) (n = 13) or equal amounts of sterile water (n = 20, control) 4 hours before the LPS dose. Pups were sacrificed at 4 days of age or sooner if they developed evidence of distress, including increased work of breathing or lethargy. Following sacrifice, the intestines were removed and placed in 10% formalin for 24 hours followed by saline. Following fixation of the intestine with formalin, the intestine was placed in paraffin block, and histologic sections were prepared and stained with hematoxylin and eosin for further analysis (18).
All of the results are expressed as mean ± standard deviation. Statistical comparisons were made using one-way analysis of variance. All of the statistical analyses were performed on raw data using GraphPad Prism 4.0 software (GraphPad, La Jolla, CA).
LPS Impairs IEC-6 Restitution In Vitro
Our results are consistent with other previously published results demonstrating that LPS impairs the ability of enterocytes to migrate across a wounded monolayer (6,9). We examined the effect of differing concentrations of LPS (75 and 100 μg/mL) on IEC-6 cell restitution in vitro. Enterocyte restitution was impaired in a dose-dependent fashion in which the highest concentration of LPS led to the smallest amount of healing (Fig. 1G). Representative digital images of control and LPS-treated (75 and 100 μg/mL) wounds at 0 (Fig. 1A, C, E) and 8 hours (Fig. 1B, D, F) are shown. These data demonstrate that LPS impairs enterocyte restitution in vitro.
IEC-6 Restitution Is Caused by Migration, Not Proliferation
To assess whether intestinal epithelial cellular proliferation was contributing to restitution of the wounded monolayer as compared with migration, control and treated wounded monolayers were incubated with BrdU, which is incorporated into proliferating cells. There was no statistical difference in the number of proliferating cells between control and LPS-treated wounds at 8 hours after wounding (Fig. 2B). A representative composite image of proliferating fluorescein isothiocyanate–stained BrdU-positive cells overlayed with the DAPI-stained image is shown in Fig. 2A.
LBP Improves Enterocyte Restitution Despite LPS Exposure In Vitro
Next, we investigated whether enterocyte migration could be restored with LBP despite exposure to LPS. We found that the higher concentrations of LBP (10 and 50 μg/mL) improved enterocyte migration with LPS exposure (100 μg/mL) so that at 24 hours, the wounds were healed to the levels of the control (Fig. 3). Enterocyte migration was not significantly different at the lowest concentration of LBP and LPS as compared with LPS alone.
Expression of TLR4 in Enterocytes
We sought to examine a possible mechanism by which enterocyte migration was improved with LBP in the face of LPS exposure. Therefore, we examined the expression of the TLR4 by RT-PCR. TLR4 expression was increased when cells were exposed to LPS (P < 0.01) and expression returned to control levels when LBP was present (Fig. 4).
LBP Treatment Did Not Affect the Degree of Intestinal Injury Incurred by the In Vivo Newborn Rat Model of NEC
Given the clearly favorable effects of LBP in our in vitro enterocyte experiments, we hypothesized that this approach would have protective effects in the neonatal rat model of NEC we and others have previously established. We investigated whether oral treatment with LBP had any protective or adverse effects on newborn intestinal injury in our established newborn rat model of NEC. In these studies, we found that the LBP dosing did not provide any untoward effects, and that the general appearance and health status of both treatment groups were undistinguishable throughout the repeated handling requirements of the NEC model protocol. At sacrifice of each animal, intestinal specimens were excised for histologic assessments and grading of NEC severity; there were no differences observed in the development of any degree of NEC between the 2 treatment groups (55% NEC in controls vs 54% in treatment) or grades >2 (35% in controls vs 30% in LBP treatment). Results and representative images are shown in Table 1 and Figure 5, respectively.
In the present study, we demonstrated that LBP improves neonatal enterocyte wound healing despite exposure to LPS in a concentration-dependent manner in vitro. This improvement in wound healing by LBP correlated with a downregulation of the LPS cellular activation receptor, TLR4, which corroborates findings by others that LPS through TLR4 mediates intestinal epithelial cell repair (6,19). LPS acts through the TLR4, which is found on enterocytes (6,8,19). In addition, the impairment in the intestinal barrier may allow translocation of endotoxin and activation of the systemic inflammatory system (20). LPS binding to TLR4 results in the release of proinflammatory cytokines and a significant systemic inflammatory response that contributes to the multiorgan system failure and death that can be seen with severe sepsis and NEC (21). TLR4 is upregulated in animals and humans with NEC, and in mice with a mutation in the TLR4 gene, there was reduced NEC severity (6,8,19).
A study by Cetin et al (6) demonstrated that LPS activation of TLR4 inhibits enterocyte migration, leading to the activation of focal adhesion kinase (FAK) and an increase in focal adhesions. In addition, a study by Leaphart et al (19) found that TLR4 immunoprecipitated with FAK, and that transfection of IEC-6 cells with siRNA against FAK significantly reversed the inhibitory effect of LPS on migration. Yet another study demonstrated that LPS leads to increased expression and function of integrins in enterocytes, which results in increased cell matrix adhesion and decreased migration (9). Together, these data indicate that LPS has a direct effect on intestinal epithelial cell migration and, in turn, repair after injury, likely through TLR4 activation.
LBP is a 50-kDa acute-phase protein synthesized primarily by hepatocytes in response to cytokines and other stimuli, including LPS and Gram-negative bacteria (10). Other cell lines have also been shown to synthesize LBP, including enterocytes (16,17). Classically, the role of LBP is to aid in LPS recognition by transferring it to mCD14, which then shuttles LPS to MD2, a coreceptor for TLR4 (10,22). This leads to activation of the cell and inflammatory response, which is important for host defense against Gram-negative bacteria (14). LBP-deficient mice have been shown to have decreased cytokine and inflammatory response to LPS but have increased susceptibility for lethal infections with Gram-negative bacteria (23).
At high concentrations, however, LBP has been shown to be protective against LPS or Gram-negative bacterial infections (13,15). In mice in vitro and in vivo, high concentrations of LBP, such as those equivalent to acute-phase response, injected intraperitoneally led to decreased cytokine release and improved survival after E coli LPS and live bacteria (15). Additionally, serum from septic patients, with acute-phase levels of LBP, incubated with monocytes decreased the binding of LPS and subsequent activation (13). LBP can inhibit cell responses to LPS by at least 3 different mechanisms (14). First, LBP transfers LPS to lipoproteins (14,24), including apoB-containing lipoprotein particles, low-density lipoprotein and very-low-density lipoprotein (25), and chylomicrons (24). Second, LBP forms complexes with LPS, which is then internalized by the cell without leading to cellular activation (14,26). Lastly, LBP was found to remove LPS already bound to mCD14-attenuating cell responses (21).
In our enterocyte wound healing model, cells were incubated without serum after treatment with LPS with or without LBP. Therefore, the action of LBP in neutralizing the impairment of wound healing by LPS was not caused by transference of LPS to lipoproteins, and because the LPS and LBP were combined for 1 hour before treatment, it is not likely that LBP removed already-bound LPS. The most likely mechanism of our results is LBP forms complexes with LPS aggregates, which may lead to internalization without cellular activation through TLR4. Another possibility is that LPS binds to mCD14, but the LPS-LBP complex shields it from direct interaction with TLR4 (14). Regardless, these data suggest that LPS impairment in enterocyte migration is mediated by TLR4, and that strategies to block this interaction may improve restitution.
In contrast to the consistently favorable effects of LBP in our in vitro experiments, there were no discernible effects of LPB in the neonatal rat model of NEC in vivo. Because the NEC induction protocol includes daily gavage dosing of LPS, we hypothesized that LBP may provide some protection in this setting. Our observation that LBP did not confer any protection with respect to neonatal rat intestinal injury in this model may be explained by issues regarding the dose selections used or the timing of the administrations (eg, single daily bolus vs other strategies). It is also possible that in this animal preparation, the LPS alone (and thus its binding by LBP) is only a component of the intestinal injury observed. This concept is consistent with clinical NEC, wherein several factors other than bacterial presence are known contributors to pathogenesis. An additional possibility is that in the single-cell-type conditions we used in vitro, the LBP could clearly elicit favorable effects, whereas the multicellular environment of intact intestinal tissue changes the observed outcomes. Although these in vivo studies were not intended to be exhaustive in evaluating the therapeutic potential for LBP in NEC, our observations at least suggest that LBP did not further enhance the LPS intestinal insult. Additional studies to determine the potential value of this therapeutic approach for NEC clearly would be required.
In conclusion, we demonstrated that LBP improves intestinal epithelial cell wound healing despite LPS exposure in enterocytes in vitro. This improvement in epithelial restitution by LBP has not been shown previously and suggests that such an approach strategy may provide a safe and novel therapy in disorders of intestinal inflammation, injury, and repair, such as NEC.
1. Mammen JM, Matthews JB. Mucosal repair in the gastrointestinal tract. Crit Care Med 2003; 31 (8 suppl):S532–S537.
2. Sturm A, Dignass AU. Epithelial restitution and wound healing in inflammatory bowel disease. World J Gastroenterol 2008; 14:348–353.
3. Caplan MS, Jilling T. The pathophysiology of necrotizing enterocolitis. NeoReviews 2001; 2:e103–e109.
4. Martin CR, Walker WA. Intestinal immune defences and the inflammatory response in necrotising enterocolitis. Semin Fetal Neonatal Med 2006; 11:369–377.
5. Lee JS, Polin RA. Treatment and prevention of necrotizing enterocolitis. Semin Neonatol 2003; 8:449–459.
6. Cetin S, Ford HR, Sysko LR, et al. Endotoxin inhibits intestinal epithelial restitution through activation of Rho-GTPase and increased focal adhesions. J Biol Chem 2004; 279:24592–24600.
7. Duffy LC, Zielezny MA, Carrion V, et al. Concordance of bacterial cultures with endotoxin and interleukin-6 in necrotizing enterocolitis. Dig Dis Sci 1997; 42:359–365.
8. Jilling T, Simon D, Lu J, et al. The roles of bacteria and TLR4 in rat and murine models of necrotizing enterocolitis. J Immunol 2006; 177:3273–3282.
9. Qureshi FG, Leaphart C, Cetin S, et al. Increased expression and function of integrins in enterocytes by endotoxin impairs epithelial restitution. Gastroenterology 2005; 128:1012–1022.
10. Zweigner J, Schumann RR, Weber JR. The role of lipopolysaccharide-binding protein in modulating the innate immune response. Microbes Infect 2006; 8:946–952.
11. Schumann RR, Leong SR, Flaggs GW, et al. Structure and function of lipopolysaccharide binding protein. Science 1990; 249:1429–1431.
12. Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431–1433.
13. Zweigner J, Gramm HJ, Singer OC, et al. High concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood 2001; 98:3800–3808.
14. Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res 2005; 11:225–229.
15. Lamping N, Dettmer R, Schröder NW, et al. LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. J Clin Invest 1998; 101:2065–2071.
16. Vreugdenhil AC, Dentener MA, Snoek AM, et al. Lipopolysaccharide binding protein and serum amyloid A secretion by human intestinal epithelial cells during the acute phase response. J Immunol 1999; 163:2792–2798.
17. Su GL, Freeswick PD, Geller DA, et al. Molecular cloning, characterization, and tissue distribution of rat lipopolysaccharide binding protein. Evidence for extrahepatic expression. J Immunol 1994; 153:743–752.
18. Giannone PJ, Alcamo AA, Schanbacher BL, et al. Poly(ADP-ribose) polymerase-1: a novel therapeutic target in necrotizing enterocolitis. Pediatr Res 2011; 70:67–71.
19. Leaphart CL, Cavallo J, Gribar SC, et al. A critical role for TLR4 in the pathogenesis of necrotizing enterocolitis by modulating intestinal injury and repair. J Immunol 2007; 179:4808–4820.
20. Anand RJ, Leaphart CL, Mollen KP, et al. The role of the intestinal barrier in the pathogenesis of necrotizing enterocolitis. Shock 2007; 27:124–133.
21. Thompson PA, Tobias PS, Viriyakosol S, et al. Lipopolysaccharide (LPS)-binding protein inhibits responses to cell-bound LPS. J Biol Chem 2003; 278:28367–28371.
22. Akira S, Sato S. Toll-like receptors and their signaling mechanisms. Scand J Infect Dis 2003; 35:555–562.
23. Jack RS, Fan X, Bernheiden M, et al. Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infection. Nature 1997; 389:742–745.
24. Vreugdenhil AC, Rousseau CH, Hartung T, et al. Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol 2003; 170:1399–1405.
25. Vreugdenhil AC, Snoek AM, van ’t Veer C, et al. LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction. J Clin Invest 2001; 107:225–234.
26. Gegner JA, Ulevitch RJ, Tobias PS. Lipopolysaccharide (LPS) signal transduction and clearance. Dual roles for LPS binding protein and membrane CD14. J Biol Chem 1995; 270:5320–5325.